Find Osemozotan Hydrochloride manufacturers, exporters & distributors on PharmaCompass

Osemozotan Hydrochloride

Osemozotan Hydrochloride

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

1 API Suppliers, 1 USDMF

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

EU WC

Listed Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: Osemozotan hydrochloride, Osemozotan hcl, 137275-80-0, Mkc-242, F0wkfypql8, 137275-80-0 (hcl)

Molecular Formula

C₁₉H₂₂ClNO₅

Molecular Weight

379.8 g/mol

InChI Key

GGNCUSDIUUCNKE-RSAXXLAASA-N

FDA UNII

F0WKFYPQL8

MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).

1 2D Structure

Osemozotan Hydrochloride

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

3-(1,3-benzodioxol-5-yloxy)-N-[[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine;hydrochloride

2.1.2 InChI

InChI=1S/C19H21NO5.ClH/c1-2-5-18-16(4-1)22-12-15(25-18)11-20-8-3-9-21-14-6-7-17-19(10-14)24-13-23-17;/h1-2,4-7,10,15,20H,3,8-9,11-13H2;1H/t15-;/m0./s1

2.1.3 InChI Key

GGNCUSDIUUCNKE-RSAXXLAASA-N

2.1.4 Canonical SMILES

C1C(OC2=CC=CC=C2O1)CNCCCOC3=CC4=C(C=C3)OCO4.Cl

2.1.5 Isomeric SMILES

C1[C@@H](OC2=CC=CC=C2O1)CNCCCOC3=CC4=C(C=C3)OCO4.Cl

2.2 Other Identifiers

2.2.1 UNII

F0WKFYPQL8

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 5-(3-((1,4-benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxole Hydrochloride

2. Mkc 242

3. Mkc-242

4. Osemozotan

2.3.2 Depositor-Supplied Synonyms

1. Osemozotan Hydrochloride

2. Osemozotan Hcl

3. 137275-80-0

4. Mkc-242

5. F0wkfypql8

6. 137275-80-0 (hcl)

7. Osemozotan (hydrochloride)

8. Mkc 242

9. 1,4-benzodioxin-2-methanamine, N-[3-(1,3-benzodioxol-5-yloxy)propyl]-2,3-dihydro-, Hydrochloride (1:1), (2s)-

10. Mci-242

11. 1,4-benzodioxin-2-methanamine, N-(3-(1,3-benzodioxol-5-yloxy)propyl)-2,3-dihydro-, Hydrochloride (1:1), (2s)-

12. 5-(3-((2s)-(1,4-benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxol

13. Unii-f0wkfypql8

14. 1,4-benzodioxin-2-methanamine, 2,3-dihydro-n-(3-(1,3-benzodioxol-5-yloxy)propyl)-, Hydrochloride, (s)-

15. Schembl678900

16. Dtxsid00929762

17. Db05339

18. Hy-100426a

19. Cs-0018819

20. 3-(1,3-benzodioxol-5-yloxy)-n-[[(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine;hydrochloride

21. 3-[(2h-1,3-benzodioxol-5-yl)oxy]-n-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]propan-1-amine--hydrogen Chloride (1/1)

22. 5-(3-((1,4-benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxole Hydrochloride, S-

2.4 Create Date

2005-08-09

3 Chemical and Physical Properties

Molecular Formula	C₁₉H₂₂ClNO₅
Molecular Weight	379.8 g/mol
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	7
Exact Mass	379.1186505 g/mol
Monoisotopic Mass	379.1186505 g/mol
Topological Polar Surface Area	58.2 Å²
Heavy Atom Count	26
Formal Charge	0
Complexity	409
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Indication

Investigated for use/treatment in anxiety disorders, depression, insomnia, and neurologic disorders.

5 Pharmacology and Biochemistry

5.1 Mechanism of Action

MN-305 is a potent and highly-selective full agonist at the serotonin 5-HT1A receptor under development by MediciNova both for the treatment of insomnia, as well as for anxiety disorders such as Generalized Anxiety Disorder (GAD). MN-305 has been evaluated in an extensive preclinical toxicology program which showed no evidence of inducing genetic mutations, immune response or cancer. MN-305 has also proved to be consistently well-tolerated in clinical safety, efficacy and pharmacokinetic studies in over 1,200 subjects.